Identification of novel azaindazole CCR1 antagonist clinical candidates
Exploring various cyclization strategies, using a submicromolar pyrazole HTS screening hit 6 as a starting point, a novel indazole based CCR1 antagonist core was discovered. This report presents the design and SAR of CCR1 indazole and azaindazole antagonists leading to the identification of three development compounds, including 19e that was advanced to early clinical trials.
AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
-
Page/Page column 155; 156
(2010/04/27)
More Articles about upstream products of 1220026-26-5